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Jingchen Shao1,2, Susann Li1,2, Lars Palmqvist1,2, Linda Fogelstrand1,2, Stella Y. Wei1,3, Kiran Busayavalasa4, 
Kui Liu4 and Viktor M. Liu1,2* 
Abstract 
PTEN acts as a phosphatase for PIP3 and negatively regulates the PI3K/AKT pathway, and p27KIP1 is a cyclin-dependent 
kinase inhibitor that regulates the G1 to S-phase transition by binding to and regulating the activity of cyclin-depend-
ent kinases. Genetic alterations of PTEN or CDKN1B (p27KIP1) are common in hematological malignancies. To better 
understand how mutations in these two genes might cooperate in leukemogenesis, we inactivated both genes in the 
hematological compartment in mice. Here, we show that the combined inactivation of Pten and Cdkn1b results in a 
more severe myeloproliferative neoplasm phenotype associated with lower hemoglobin, enlarged spleen and liver, 
and shorter lifespan compared to inactivation of Pten alone. More severe anemia and increased myeloid infiltration 
and destruction of the spleen contributed to the earlier death of these mice, and elevated p-AKT, cyclin D1, and cyclin 
D3 might contribute to the development of this phenotype. In conclusion, PTEN and p27KIP1 cooperate in tumor sup-
pression in the hematological compartment.
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Background
PTEN (phosphatase and tension homolog deleted on 
chromosome 10) is a tumor suppressor gene located on 
chromosome 10q23 and is one of the most commonly 
mutated or deleted genes in human cancers, including 
acute lymphoblastic leukemia, juvenile myelomonocytic 
leukemia, and non-Hodgkin’s lymphoma [1, 2]. PTEN 
acts as a phosphatase for phosphatidylinositol-3,4,5-
trisphosphate (PIP3) and negatively regulates the phos-
phatidylinositol 3-kinase (PI3K)/AKT pathway [3]. The 
CDKN1B gene encodes p27KIP1, which belongs to the 
Cip/Kip family of cyclin-dependent kinase inhibitors. 
p27KIP1 is a key regulator of the G1 to S-phase transition 
by inhibiting cyclinD1/CDK4 and cyclinE/CDK2 com-
plexes [4]. Deletions and other cytogenetic aberrations 
involving CDKN1B have been reported in a variety of 
leukemias [5–7]. In addition, CDKN1B expression can be 
a useful prognostic molecular marker for acute myeloid 
leukemia, where low CDKN1B expression is associated 
with high proliferation and, therefore, with a favorable 
response to chemotherapy [6]. Inactivation of the tumor-
suppressor gene PTEN and lack of CDKN1B expression 
have been detected in some kinds of cancer, including 
most advanced prostate cancers and lymphomas [8, 9]. 
It has been shown that the combined loss of PTEN and 
p27KIP1 is associated with tumor cell proliferation and 
increased risk of recurrent disease in localized prostate 
cancer [10]. Loss of PTEN expression is more frequent in 
anaplastic large-cell lymphoma, which strongly correlates 
with the loss of CDKN1B expression [9].
Targeted disruption of the murine Cdkn1b gene causes 
a gene dose-dependent increase in animal size without 
other gross morphologic abnormalities [11], and dele-
tion of Pten in the hematopoietic compartment in mice 
promotes excessive proliferation of leukemogenic stem 
cells resulting in the development of myeloproliferative 
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neoplasm (MPN) followed by acute leukemia [12]. In 
mice, concomitant inactivation of Pten and Cdkn1b 
accelerates spontaneous neoplastic transformation of 
prostate cancer [8]. In order to better understand the 
relation and clinical relevance of these two genes in the 
pathogenesis of hematological malignancies, we used 
Cre recombinase to simultaneously inactivate Pten and 
Cdkn1b in the hematopoietic compartment.
Results and discussion
To determine the impact of combined deficiency of 
PTEN and p27KIP1 in the hematopoietic compartment, 
we injected pI–pC into PCM, PM, CM and Ctrl mice. 
Consistent with previous studies [13], all PM mice died 
from MPN by 98  days after pI–pC injections (median 
survival 62 days), whereas CM and Ctrl mice lived much 
longer and no MPN phenotype was observed in CM mice. 
However, the maximum survival of PCM mice was only 
30  days (median 24  days; p  <  0.001 versus PM; Fig.  1a). 
Two weeks after pI–pC injections, white blood cell counts 
were 20.8 × 109 cells/L in PCM mice compared with mean 
counts of 18.3 × 109, 13.9 × 109 and 13.6 × 109 cells/L for 
PM, CM and Ctrl mice, respectively (Fig. 1b). However, no 
morphological changes and no increase in the amounts of 
immature cells, including myeloblasts, could be detected 
in the blood and bone marrow in PCM mice compared 
with the other three groups (Fig. 1c, e). More severe ane-
mia and more architectural disruption of the spleen were 
observed in PCM mice (Fig. 1d, e).
Spleen and liver weights in PCM mice increased by 
2.3–5.6 and 1.2–2.4-fold, respectively, compared with 
PM, CM and Ctrl mice (Fig.  2a, b). Fluorescence-acti-
vated cell sorting analysis showed an increased pro-
portion of CD11b+/Gr1+ and LSK [Lineage-negative 
(lin−), Sca-1+, c-Kit+] cells in the spleen of PCM mice 
compared to PM, CM and Ctrl mice (p  <  0.05; Fig.  2c). 
Splenocytes from PCM mice produced more colo-
nies compared with the other three groups (Fig.  2d). In 
bone marrow, there were no differences in the percent-
age of LSK cells (Fig.  2e). No increased colony forma-
tion in PCM mice was observed compared to PM mice 
when replated, and both groups had more colonies than 
the Ctrl mice when replated (Fig.  2f ). Taken together, 
the phenotype in PCM mice is severe MPN rather than 
acute leukemia based on the criteria for classification of 
hematopoietic neoplasms in mice [14]. More severe ane-
mia and increased myeloid infiltration and destruction of 
the spleen likely contributed to the earlier death of PCM 
mice compared with PM mice.
We performed Western blot analysis to determine the 
knock-out efficiency and the consequences of inactivat-
ing PTEN and p27KIP1 on downstream molecules. Defi-
ciency of PTEN or p27KIP1 was observed in the respective 
knock-out mice (Fig. 2g). It has been shown that PTEN 
activity leads to the induction of p27KIP1, which in turn 
can negatively regulate the transition through the cell 
cycle [15]. However, the association between PTEN and 
p27KIP1 might be different in different kinds of tissues. A 
lack of convincing correlation between PTEN and p27KIP1 
has been reported for ovarian carcinomas, indicating 
the possible existence of p27KIP1-independent pathways 
downstream of PTEN [16]. In our study, we found that 
expression of p27KIP1 was reduced in the splenocytes of 
PM mice. PCM mice had higher phosphorylated AKT 
compared to PM, CM, and Ctrl mice (Fig. 2g), and cyc-
lin D1 and cyclin D3 expression levels were elevated in 
PCM and PM mice. However, the levels of phosphoryl-
ated ERK1/2 were similar in all groups of mice. Previous 
studies showed the synergistic activity of PI3K/mTOR 
and JAK2 signaling pathway in the myeloproliferative 
neoplasms [17, 18], therefore it will be interesting to 
study the JAK2 activity in PTEN and p27KIP1 knockout 
mice model.
In conclusion, our results show that PTEN deficiency 
can promote tumor progression by a decrease in p27KIP1 
levels in the hematological compartment and that PTEN 
and p27KIP1 have a cooperative role in leukemia suppres-
sion. In addition, our results show that elevated phos-
phorylated AKT, cyclin D1, and cyclin D3 might play 




Mice with conditional Ptenfl/fl alleles (designated P) 
with a mixed genomic background of 129S4/SvJae and 
C57BL/6J were bred with Cdkn1bfl/fl mice (designated C) 
to generate PC mice. PC mice were bred with mice har-
boring the interferon (IFN)-inducible Mx1-Cre transgene 
(designated M) to generate PCM (Ptenfl/fl Cdkn1bfl/fl 
Mx1-Cre), PM (Ptenfl/fl Mx1-Cre), and CM (Cdkn1bfl/
fl Mx1-Cre) mice. Mice without Mx1-Cre were used as 
healthy controls (designated Ctrl).
The mice were housed under controlled environmen-
tal conditions with free access to water and food. Illu-
mination was on between 0600 and 1800  h. All mice 
were monitored daily. Groups of 4-week-old mice were 
injected with 400 µg polyinosinic-polycytidylic acid (pI–
pC; Sigma, St Louis, MO). Blood was taken weekly and 
analyzed with a hematology analyzer KX-21 (Sysmex 
Europe, Norderstedt, Hamburg, Germany). Three weeks 
after injection, groups of mice were sacrificed and their 
tissues were harvested for further analysis. Mice were 
euthanized by cervical dislocation after carbon dioxide 
inhalation. In addition, groups of mice were kept for a 
survival study. If mice had ruffled fur and become listless 
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or lost more than 10  % of their body weight, they were 
euthanized. All experimental protocols were approved by 
the regional ethical committee of the University of Goth-
enburg, Sweden.
Genotyping
Genotyping was performed by PCR amplification of 
genomic DNA extracted from mouse tails. The Ptenfl 
allele was detected with forward primer 5′-CAAG 
CACTCTGCGAACTGAG-3′ and reverse primer 5′-AA 
GTTTTTGAAGGCAAGATGC-3′, yielding a 328-bp 
fragment from the Ptenfl allele and a 156-bp frag-
ment from the Pten+ allele. The P27fl allele was 
detected with forward primer 5′-TAGGGGAAAT 
GGATAGTAGATGTTAGGACC-3′ and reverse primer 
5 ′ -G GTATA ATATG GA A AGTGAC TC TA ATG G 
CC-3′, yielding a 400-bp fragment from the P27fl allele 
and a 370-bp fragment from the P27+ allele. The Mx1-
Cre transgene was detected with forward primer 
5′-GCGGTCTGGCAGTAAAAACTATC-3′ (oIMR 1084) 
and reverse primer 5′-GTGAAACAGCATTGCTGTC 
ACTT-3′ (oIMR 1085) to yield a 100 bp fragment.
Fluorescence‑activated cell sorting, colony assays, 
and histology
Splenocytes and bone marrow cells were incubated 
with antibodies against Gr1 (PE-Cy7/RB6-8C5), CD11b 
(V450/M1/70), c-kit (PE/2B8), Sca1 (PE-Cy7/D7), Lin- 
(FITC) and CD45 (V500/30-F11) and analyzed with 
FACS Diva software (BD Biosciences, San Jose, CA, 
USA). For colony assays, splenocytes (1 × 105) and bone 
marrow cells (2  ×  104) harvested from experimental 
mice were seeded in duplicate wells in methylcellulose 
medium (MethoCult M3434; StemCell Technologies, 
Vancouver, BC, Canada). Six days later, the numbers of 
colonies were scored. For bone marrow cells, on the 
7th  day the cultured cells were washed, collected, and 
replated. Histology was performed as described [19, 20].
Fig. 1 Survival, white blood cell counts, hemoglobin level, and histological analysis of all groups of mice. a Kaplan–Meier survival plots for PCM 
(n = 6), PM (n = 12), CM (n = 12) and Ctrl mice (n = 12). b White blood cell counts of PCM, PM, CM and Ctrl mice (n = 8 in each group). Blood was 
analyzed before and 1 and 2 weeks after pI–pC injections. c Blood hemoglobin concentrations of mice at 3 weeks after pI–pC injections. d Photo-
graphs of bone marrow (top panels) and spleen (bottom panels) sections (hematoxylin and eosin staining). Magnification was ×100/1.40 for bone 
marrow, ×20/0.50 for spleens
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Western blots
Tissue pieces (50–100  mg) were lysed in ice-cold buffer 
(50  mM Tris–HCl, 120  mM NaCl, 5  mM MgCl2, 1  % 
Triton X-100, 0.1 % sodium dodecyl sulfate, 1 % NP-40, 
20 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 2 mM 
orthovanadate, and the Complete Mini protease inhibitor 
cocktail). Lysates were homogenized, and centrifuged at 
20,000g for 20  min, and equal amounts of total protein 
of the supernatant were size-fractionated on 10–15  % 
sodium dodecyl sulfate polyacrylamide gels. The pro-
teins were transferred onto nitrocellulose membranes 
and incubated with antibodies against phosphorylated 
ERK1/2 (9106), total ERK (9102), phosphorylated AKT 
(9271), PTEN (9559), p27KIP1 (2552; Cell Signaling, 
Fig. 2 PCM mice exhibit massive hepatosplenomegaly, extramedullary hematopoiesis, and increased colony growth of splenocytes. a Spleen and 
b liver weight [relative to total body weight (bwt)] in PCM (n = 5), PM (n = 5), CM (n = 5), and Ctrl (n = 5) mice 3 weeks after pI–pC injections.  
c Colony-forming ability of splenocytes isolated from PCM (n = 3), PM (n = 3), CM (n = 3) and Ctrl (n = 3) mice around 3 weeks after pI–pC 
injections. GEMM colony-forming unit-granulocyte, erythroid, macrophage, megakaryocyte, GM colony-forming unit-granulocyte, macrophage, 
E burst-forming unit-erythroid. d Representative flow cytometry plots of splenocytes with antibodies recognizing CD11b, Gr-1, c-Kit, Sca1 and 
Lineage-negative. The mean percentage of double-positive splenocytes from PCM (n = 3), PM (n = 3), CM (n = 3), and Ctrl (n = 3) mice is indicated. 
e Percentage of LSK cells in bone marrow from PCM (n = 3), PM (n = 3), CM (n = 3), and Ctrl (n = 3) mice, as determined with flow cytometry.  
f Colony-forming ability of bone marrow from PCM (n = 3), PM (n = 3), CM (n = 3), and Ctrl (n = 3) mice. g Western blots of protein extracts from 
splenocytes of PCM (n = 2), PM (n = 2), CM (n = 2), and Ctrl (n = 2) mice at the 3rd week after pI–pC injection. Actin was used as the loading control
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Danvers, MA), Cyclin D1(sc-718), Cyclin D3 (sc-182), 
and Beta-actin (sc-47778; Santa Cruz Biotechnology, Inc., 
Dallas, TX). Protein bands were visualized with a horse-
radish peroxidase-conjugated secondary antibody (170-
5046 and 170-5047; Bio-Rad Laboratories, Inc., Hercules, 
California) and the Enhanced Chemiluminescence Kit 
(Amersham, Little Chalfont, Buckinghamshire, United 
Kingdom). Band density was measured by Quantity One 
software (Bio-Rad Laboratories, Inc. USA).
Statistical analyses
Data are plotted as the mean ± SEM. Differences in the 
concentrations and percentages of white blood cells, the 
colony-forming ability of hematopoietic cells, and the 
proliferation of cells in culture were determined with Stu-
dent’s t test. Differences in mouse survival were assessed 
by the Mann–Whitney U test.
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